Benzinga - by Lisa Levin, Benzinga Editor.
The Dow Jones closed lower by over 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
Pacific Health Care Organization
- The Trade: Pacific Health Care Organization, Inc. (OTC: PFHO) CEO and President Tom Kubota acquired a total of 55,000 shares an average price of $0.80. To acquire these shares, it cost around $44,000.
- What’s Happening: The company reported net income of $176,427 or $0.01 per share for the three months ended June 30, 2023.
- What Pacific Health Care Organization Does: Pacific Health Care Organization Inc is a specialty workers' compensation managed care company.
- The Trade: Cineverse Corp. (NASDAQ: CNVS) CFO Mark Lindsey acquired a total of 10,000 shares at an average price of $1.15. To acquire these shares, it cost around $11,500.
- What’s Happening: Cineverse reported worse-than-expected first-quarter financial results.
- What Cineverse Does: Cineverse Corp is a streaming technology and entertainment company. It operates portfolios of owned and operated streaming channels, all powered by its, proprietary technology platform.
CURO Group Holdings
- The Trade: CURO Group Holdings Corp. (NYSE: CURO) CEO Douglas Clark acquired a total of 20,000 shares at an average price of $1.04. The insider spent $20,734 to buy those shares. The company’s Director Heath Chadwick Faulkner also bought 16,000 shares.
- What’s Happening: CURO Group posted a wider-than-expected second-quarter loss.
- What CURO Group Does: CURO Group Holdings Corp is a consumer finance company serving a full spectrum of non-prime, near-prime and prime consumers in portions of the U.S. and Canada.
Don’t forget to check out our premarket coverage here
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.